top-lin cystinosi data cf data lower price
eloxx report top-lin phase ii data first cohort cystinosi patient
safeti primari endpoint thu far well toler report
sae lower white blood cell cystin level seen reduct clinic
benefici level observ howev compani note treat
cohort higher baselin cystin level previous enrol cystagon trial
protocol modif explor cohort initi also
on-going phase ii studi mutant cystic fibrosi patient top-lin data
reiter overweight rate howev lower price target
top-lin cystinosi phase ii data eloxx develop treat cystinosi
ultra-rar lysosom storag diseas mediat nonsens mutat ctn
gene result impair cystinosin protein unabl export cystin
lysosom reduc cystin level nmol/mg cystine/mg
protein consid goal therapi eloxx conduct dose rang
phase ii studi nephropath csytinosi patient primari endpoint safeti
secondari endpoint includ cystin level establish go-forward dose
eloxx report top-lin phase ii data first cohort three homozyg
cystinosi patient dose subcu mg/kg cohort baselin
cystin level rang nmol cystine/mg protein
cystin lower seen dose greater mg/kg even achiev statist
meaning reduct mg/kg dose compani report overal
clinic benefici reduct reach howev compani note
treat cohort higher baselin cystin level prior cystagon trial
enrol patient less nmol cystine/mg protein remain well-
toler mild inject site reaction observ sae report
kidney function preserv post-transpl patient eloxx explor
potenti protocol modif initi cohort
top-lin cf phase ii data on-track phase ii studi enrol
patient europ mutat
preval nonsens mutat affect cf patient patient receiv
daili subcu inject establish go-forward dose base
chang sweat chlorid safeti primari endpoint measur
eloxx expect complet enrol top-lin phase ii data
may fail clinic fail gain regulatori approv eloxx may unabl file
ind compani like requir futur fund
eloxx develop drug treat genet diseas caus nonsens mutat
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
invest recommend reiter overweight rate howev trim price target
increas discount rate form roll forward discount period
price target base project enterpris valu million
million
valu cf million million appli
standard multipl sale million discount back
valu cf europ million
million appli multipl sale million discount back higher
increas discount rate form reflect delay
phase ii enrol could adjust base data
valu cystinosi million million appli
multipl sale million discount back higher
valu cystinosi europ million form million appli
multipl sale million discount back
add million form million eloxx preclin usher syndrom program
could enter clinic
eloxx end cash million eloxx owe debt svb westriv thu
subtract project net debt million vs prior net debt
divid project market cap million million share arriv
lower price target pleas see exhibit
page
thousand except per share
product sold
research develop
gener administr
incom expens
net loss attribut common stockhold
compani report piper sandler estim
current disclosur inform compani found
